/PRNewswire/ The "Induced Pluripotent Stem Cell (iPSC) Global Market Report 2022, By Derived Cell Type, By Application, By End-User" report has been added.
Equipment to produce a vaccine is installed at Unigen’s factory in Ikeda, Gifu Prefecture, in December. (Sho Ito)
Japanese drug companies are moving at an “unprecedented” pace to develop COVID-19 vaccines, but their foreign rivals have already won the race.
Although the government has committed hundreds of billions of yen for a game-changing medicine in the novel coronavirus pandemic, the domestic industry is just not set up for speedy vaccine development, and such projects have long been a low priority for Japanese pharmaceutical businesses.
Japan plans to begin inoculating the population in late February at the earliest. As it does with so many pharmaceuticals, the country will rely on an import, the Pfizer-BioNTech vaccine.